Interstitial fluid pressure (P IF ) is one of the determinants of transcapillary fluid flux and thereby interstitial fluid volume. Cell-mediated control of P IF regulates fluid content in the loose interstitial connective tissues that surround the capillary bed. To maintain a normal P IF in dermis, ␤1 integrins mediate the tensile strength applied by connective tissue cells on the extracellular matrix. Platelet-derived growth factor (PDGF)-BB normalizes anaphylaxis-induced reduction of P IF . Anti-␤3 integrin IgG and a cyclic RGD peptide that inhibits the ␣V␤3 integrin blocked the ability of PDGF-BB to normalize the lowered P IF resulting from mast cell degranulation. PDGF-BB was unable to normalize P IF lowered as a result of mast cell degranulation in ␤3-negative mice. Monoclonal anti-␤3 integrin IgG had no effect on P IF in normal mouse dermis. In contrast, administration of anti-␤1 integrin IgM lowered P IF in normal dermis but had no effect on PDGF-BB-induced normalization of P IF after anaphylaxis. Furthermore, collagen gel contraction mediated by wild-type mouse embryonal fibroblasts were only marginally affected by function-blocking anti-␤1 integrin antibodies, especially in the presence of PDGF-BB. In contrast, contraction mediated by ␣V-negative mouse embryonic fibroblasts was completely blocked by anti-␤1 integrin antibodies, even after stimulation with PDGF-BB. These results show a previously unrecognized in vivo function for the ␣V␤3 integrin, as a participant in the control of P IF during inflammatory reactions. Furthermore, our data demonstrate that PDGF-BB induces connective tissue cells to generate tensile forces via ␣V␤3 during such reactions. (Circ Res. 2006;98:635-641.) 
F luid constantly filters across the capillary wall into the surrounding loose interstitial connective tissues. The rate of fluid filtration is determined by the net pressure difference across the capillary, ie, the difference in the colloid osmotic pressures in plasma (COP PL ) and interstitial fluid (COP IF ), and between hydrostatic capillary pressure (HPC) and interstitial fluid pressure (P IF ) and a constant expressing capillary area and permeability (for a review see, Aukland and Reed 1 ). Normally, P IF will prevent changes in interstitial volume because increased capillary filtration will raise interstitial volume and thereby P IF , which in turn acts across the capillary to limit further capillary filtration. Reduced capillary filtration will cause opposite changes in interstitial fluid volume and P IF , but again changes in P IF act to limit changes in interstitial volume. 1 P IF has commonly been described as a function of interstitial volume and compliance such that P IF is increasing with increasing interstitial volume, but not necessarily in a linear fashion. 1 In contrast to the role in maintaining a constant interstitial volume and the relationship normally described by compliance, a reduction in P IF has been observed to provide the driving force for edema formation during inflammation and burn injuries, with P IF falling in some cases to levels as low as Ϫ150 mm Hg. 2 Through a series of studies, we have demonstrated that cells in loose connective tissue actively control P IF and thereby fluid fluxes across capillary walls, 2 and this study presents further details on this cellular control of P IF and thereby on the control of interstitial volume and edema formation.
Injection of anti-␤1 integrin IgG in rat dermis lowers P IF and leads to rapid edema formation. 3 Monoclonal IgG specific for the collagen/laminin-binding integrin ␣2␤1, but not monoclonal anti-␣1␤1 IgG, induces a reduction in P IF in rat dermis, suggesting that ␣2␤1 is of particular importance among the ␤1 integrins. Several proinflammatory mediators such as interleukin (IL)-1␤, tumor necrosis factor-␣, IL-6, and the prostaglandins (PGs) E 1 and I 2 , as well as the phosphatidyl inositol 3-kinase (PI3K) inhibitor Wortmannin, all act to reduce dermal P IF . 2,4 -6 A reduced P IF , resulting from blockade of ␤1 integrin function or inflammatory reactions can be normalized by a prostaglandin F analog and by platelet-derived growth factor (PDGF)-BB, but not PDGF-AA or fibroblast growth factor. 5, 7 By using mice with a knockout lesion for PDGF␤ receptor-induced activation of PI3K, we demonstrated that the normalization of P IF that normally can be induced by PDGF-BB was completely abolished. Consequently, PI3K is necessary to induce the P IF -normalizing effects of PDGF-BB. 8 We have proposed a model for how connective tissue cells participate in the control of P IF . According to this model, connective tissue cells, ie, fibrocytes and/or pericytes, exert a tension on the collagen/microfibrillar network via integrins, eg, ␣2␤1. 2, 9, 10 This collagen/microfibrillar network in turn restrains the intrinsic swelling properties of the hyaluronan/proteoglycan ground substance of the extracellular matrix (ECM). 11 If the ground substance is allowed to swell, P IF will be reduced and if fluid is supplied by an intact blood circulation edema will form. Conversely, an increased cellular tension will increase P IF and filter fluid back across the capillaries or into the lymphatics.
Fibroblast-mediated collagen gel contraction 12 depends on ␤1 integrins and is stimulated by PDGF. [13] [14] [15] PDGF-BBstimulated collagen gel contraction is mediated by ␣V␤3 integrins in experimental conditions when ␤1 integrins are absent or functionally perturbed. 16, 17 Furthermore, forced expression of the ␣V subunit in human osteosarcoma cells that lack endogenous expression of the collagen-binding integrin ␣2␤1 promotes collagen gel contraction by these cells. 18 These findings are consistent with an earlier report suggesting that the ␣V␤3 integrin, under certain conditions, may function as a collagen receptor that mediates collagen gel contraction. 19 Consistent similarities in the control of cell-mediated collagen-gel contraction in vitro and P IF and edema formation in vivo have been observed. [3] [4] [5] 7, 8 Against this background, it seemed reasonable to hypothesize that ␣V␤3 integrins are involved in PDGF-BB-directed control of P IF in vivo. The present study was performed to test this hypothesis.
Materials and Methods

Animals
Female C57BL/6 and BALB/c mice were from Møllegaard (Lille Skensved, Denmark). Mice were fed ad libitum before experiments and anesthetized by an SC injection of a 1:1 mixture of Midazolam (Dormicum, Roche, Basel, Switzerland) combined with fentanyl/ fluanisone (Hypnorm, Janssen Pharmaceutica, Beerse, Belgium) (0.1 mL/10 g body weight). ␤3-Null mice on C57BL/6 -129S4 background 20,21 were backcrossed for 7 generations against BALB/c mice (Jackson Laboratories, Bar Harbor, Me) in the Massachusetts Institute of Technology facility and donated by Dr Richard Hynes (Massachusetts Institute of Technology). These mice are viable and fertile. The mice were catheterized in the right carotid artery to monitor arterial blood pressure and in the external jugular vein for IV injections. Circulatory arrest was induced by an IV injection of saturated KCl. Experiments were performed with the approval of and in accordance with the recommendations laid down by the Norwegian State Commission for Laboratory Animals.
PCR Analysis
Three-primer PCR was performed to genotype mouse tail DNA samples for screening the ␤3 integrin genotype. Common forward primer 1 (5Ј CTTAGACACCTGCTACGGGC 3Ј) lay 5Ј of the pgk-neo cassette; reverse primer 2 (5Ј CACGAGACTAGT-GAGACGTG 3Ј) was neo specific and reverse primer 3 (5Ј CCT-GCCTGAGGCTGAGTG 3Ј) was wild-type specific. The PCR conditions (95°C, 10 minutes; followed by 30 cycles of 95°C, 1 minute; 66°C, 2 minutes; 72°C, 2 minutes; and finally 72°C, 10 minutes) yielded products of 538 bp (mutant) and 446 bp (wild-type).
Collagen Gel Contraction
Mouse embryonic fibroblasts were established by standard protocols 22 from embryonic day (E) 9 to E10 integrin ␣V-negative and wild-type littermate embryos. 23 Cells were grown in DMEM supplemented with 10% FBS and antibiotics in culture dishes and flasks precoated overnight at Ϸ8°C with 50 g/mL native collagen (Vitrogen 100, Cohesion, Palo Alto, Calif) in PBS. Collagen gel contraction was quantified as described elsewhere. 14 Briefly, 96-well plates were blocked in BSA overnight at 37°C and then washed in PBS. A collagen solution was made up from 5 parts doubleconcentrated DMEM, 1 part 0.2 mol/L HEPES (pH 8.0), and 4 parts collagen type I (Vitrogen 100, 3 mg/mL). Cells were washed 2 times in DMEM and diluted to a final concentration of 10 6 cells/mL in the same medium. One part cell suspension was mixed with 9 parts collagen solution. Cell-collagen suspension (100 L) was added to each well, and gels were allowed to form for 1.5 hour at 37°C. Gels were detached by the ejection of 100 L of DMEM, with or without 50 ng/mL PDGF-BB and with or without 800 g/mL polyclonal anti-rat integrin ␤1 IgG 24 into the wells. The relaxed, floating gels were further incubated at 37°C and gel diameters were measured microscopically at the indicated time points. The degree of contraction is presented as the gel area as a percentage of the original area. Each experiment was performed with a minimum of 3 samples per condition.
P IF Measurements
P IF was measured using sharpened glass capillaries (tip diameter, 3 to 5 m) filled with 0.5 mol/L NaCl colored with Evans Blue and connected to a servocontrolled counterpressure system. 25, 26 The punctures were performed through intact skin using a stereomicroscope (Wild M5, Heerbrugg, Switzerland) with the pipette tip located 0.3 to 0.5 mm below the skin. Care was taken not to cause any compression or retraction of the skin while puncturing. The animal was placed in a supine position and the left hind paw was carefully fixed to the table with surgical tape. Control P IF was measured with the circulation still intact. C48/80 (200 g, Sigma, St Louis, Mo) in 0.1 mL of 0.9% NaCl was injected IV and allowed to circulate for 2 minutes before circulatory arrest was induced. C48/80 causes a reduction of the P IF through degranulation of mast cells. Circulatory arrest was induced to prevent a potential underestimation of the lowered P IF caused by an increase in interstitial fluid volume as a result of increased transcapillary fluid flux. The lowering of the P IF was monitored for 30 minutes and test substances were then injected subdermally in a volume of 1 L of buffer (0.14 mol/L NaCl, 4.7 mmol/L KCl, 0.65 mmol/L MgSO 4 , 1.2 mmol/L CaCl 2 , 10 mmol/L HEPES, pH 7.4) using a 10-L chromatography syringe (Hamilton, Bonaduz, Switzerland) with a 33-or 34-gauge needle. Measurements were then continued for another 60 minutes. Test substances used were PDGF-BB, anti-rat integrin ␤1 (Ha2/5) monoclonal IgM (BD Pharmingen, San Diego, Calif), anti-mouse integrin ␤3 (HM␤3) monoclonal IgG (BD Pharmingen), and cyclo (Arg-Gly-Asp-D-Phe-Val) (Bachem, Bubendorf, Switzerland). The test substances were administered either separately or in combination. The pressure measurements were averaged in the following periods: 0 to 10, 11 to 20, 21 to 30, 31 to 40, 41 to 50, 51 to 60, 61 to 75, and 76 to 90 minutes after C48/80 injection. For a measurement to be accepted, the following criteria had to be fulfilled: (1) feedback gain could be changed without changing the pressure; (2) applying suction to the pipette by the pump increased the resistance in the pipette (this ensured contact between the pipette and the interstitial fluid, ie, the pipette was open); and (3) zero pressure did not change during the measurement.
PDGF-BB in Serum and Tissue
Eight wild-type BALB/c mice were anesthetized with an SC injection of 0.2 mL Ketalar/Dormicum and supplied with a catheter in the right jugular vein. The mice received an IV injection of 0.1 mL of NaCl (control, nϭ4) or 0.1 mL 200 g C48/80 (experiment, nϭ4). Blood samples were obtained via the intravenous catheter or heart puncture 2 minutes later. Circulatory arrest was then induced by an IV injection of saturated KCl and the skin on one hind paw was removed. Blood (Ϸ200 L) was immediately added to 200 L of 3.8% citrate buffer containing 0.1 mol/L benzamidine, 10 3 U/mL Trasylol, and protease inhibitors (Complete, Roche Diagnostics, Mannheim, Germany). The mixture was centrifuged at 3000g for 20 minutes in a centrifuge without a brake. The skin samples (Ϸ100 mg) were minced with a scalpel and placed into tubes containing 200 L of extraction buffer (50 mmol/L Tris-HCl pH 7.4, 5 mmol/L EDTA, 1% NP-40, 1% Na-deoxycholate, 50 mmol/L NaF, 50 mmol/L ␤-glycerophosphate and protease inhibitors [Complete, Roche Diagnostics]) for 24 hours. Tissue samples were freeze thawed twice during this period. PDGF-BB was determined in the supernatants of serum and tissue extracts using a Mouse/Rat PDGF-BB Immunoassay (R&D Systems, Minneapolis, Minn). The procedure described in the kit was followed and Calibrator diluent RD6 -3 was used to dilute the samples. The detection limit for the assay given by the manufacturer was 7.7 pg/mL (range 4.0 to 19.3 pg/mL).
Statistical Analysis
All values are meanϮSD. Data were recorded for each 10-minute period within each experimental group up to 60 minutes and thereafter in 15 minutes periods. Each experimental group was compared for control and 21 to 30 minutes and 51 to 60 minutes using 1-way ANOVA followed by post hoc Bonferroni and Student-Newman-Keul tests. A value of PϽ0.05 was considered statistically significant.
Results
A subdermal injection of 0.9 g of anti-␤1 IgM in a volume of 1 L lowered P IF in C57BL/6 mouse dermis. Control P IF averaged Ϫ0.96Ϯ0.51 mm Hg before subdermal injection and averaged Ϫ3.08Ϯ1.63 mm Hg 60 minutes after IgM injection (PϽ0.05 compared with control). This is in agreement with earlier results showing that ␤1 integrins are involved in controlling P IF in naive dermis. 3, 7 A subdermal injection of 0.25 g of monoclonal anti-␤3 integrin IgG had, however, no significant effect on P IF during the investigated time period (Table) (PϾ0.05), indicating that ␤3 integrin(s) is not necessary to maintain dermal P IF . In the present experi-mental protocol, the test substance was injected some distance from the site where the micropuncture needle was inserted. A higher dose of the anti-␤1 antibody than the anti-␤3 IgG was therefore used because IgM could be assumed to diffuse less rapidly than the IgG to reach effective concentrations in the tissue segment where the P IF was recorded.
The reduction of P IF in mouse dermis resulting from systemic administration of C48/80 is reversed by a local instilment of PDGF-BB ( Figure 1 and the Table) as previ- Figure 1 . Integrin ␤3 is required for normalization of P IF by PDGF-BB after mast cell degranulation in mouse. P IF was measured using a micropuncture technique as described in Material and Methods. C48/80 was used to induce mast cell degranulation. C48/80 was injected intravenously and allowed to circulate for 2 minutes before circulatory arrest was induced. P IF was monitored for 30 minutes before PDGF-BB alone (diamonds) or together with anti-rat ␤1 integrin monoclonal IgM (squares), antimouse ␤3 integrin monoclonal IgG (triangles) or a cyclic ␣V-inhibitor (circles) were injected subdermally. To allow comparison of the temporal changes, P IF values were normalized such that the P IF value recorded at the start of the experiment was set to 0% and P IF recorded 30 minutes after injection of C48/80 was set to Ϫ100%. For absolute P IF values and statistical analysis, see the ously reported. 8 The P IF -normalizing effect of 0.2 ng PDGF-BB was not affected in C57BL/6 mouse dermis by simultaneous instilment of 0.9 g of monoclonal anti-␤1 integrin IgM (Figure 1 and the Table) . Instilment of 0.25 g of anti-␤3 integrin IgG, together with the PDGF-BB, however, abolished the capability of the latter to normalize P IF (Figure 1 and the Table) . Furthermore, the P IF normalizing effect of PDGF-BB was abolished when it was instilled together with 500 mol/L of the cyclic ␣V␤3 inhibitor cyclo (Arg-Gly-Asp-D-Phe-Val) in a volume of 1 L (Figure 1 and the Table) . The IC 50 of this peptide for inhibition of 125 I-vi-tronectin binding to immobilized recombinant ␣V␤3 integrin is 24 nmol/L and 2000 nmol/L for ␣V␤5, 27 and in the range of 0.6 to 4.4 mol/L for ␣V␤3 and Ͼ100 mol/L for ␣5␤1-mediated cell adhesion. 28 The test substance was injected at some distance from the site where the micropuncture needle was inserted, leading to at least a 20-fold dilution of the test substance during its diffusion to the tissue segment in which the P IF was recorded. Thus, the effective concentration of the inhibitor can be calculated to be Ͻ25 mol/L in the present experiments, suggesting that the effect of the inhibitor on P IF is caused by blockage of ␣V␤3 and not ␣5␤1.
To further investigate the possibility that the P IFnormalizing effect of PDGF-BB in mouse dermis was dependent on ␤3 integrins, we took advantage of ␤3-deficient mice. 20 These mice carry a null mutation of the ␤3 integrin gene but are fertile and develop normally, except for disturbances of platelet and osteoclast functions leading to thrombastenia 20 and osteosclerosis. 21 Systemic administration of C48/80 in wild-type and ␤3 null BALB/c mice reduced dermal P IF (Figure 2 and the Table) . Local instilment of PDGF-BB normalized the reduced P IF in wild-type, but not in the dermis of ␤3 integrin null, mice ( Figure 2 and the Table) . Together, our results strongly suggest that PDGF-BB acts on ␤3, but not on ␤1, integrins during the restoration of a normal dermal P IF that had been reduced by mast cell degranulation.
To validate the in vivo data suggesting a role of the ␣V␤3 integrin in contractile processes, we took advantage of mouse embryonic fibroblasts (MEF) isolated from ␣V-negative mice 23 and compared the ability of these cells to contract collagen gels in vitro with wild-type MEF. Wild-type and ␣V-negative MEF both contracted collagen gels ( Figure 3A  and 3B ). Collagen-gel contraction mediated by the ␣Vnegative cells was completely inhibited by anti-␤1 integrin IgG, whereas the same IgG was unable to completely inhibit the contraction mediated by wild-type MEF ( Figure 3A) . PDGF-BB only marginally stimulated contraction by the wild-type MEF, but restored the ability of these cells to contract collagen gels in the presence of anti-␤1 integrin IgG Figure 2 . PDGF-BB is not able to normalize P IF lowered after mast cell degranulation in dermis of ␤3 integrin null mice. C48/80 was injected intravenously and allowed to circulate for 2 minutes before circulatory arrest was induced. P IF was monitored for 30 minutes before PDGF-BB was injected subdermally. In ␤3 integrin wild-type mice, PDGF-BB was able to restore a lowered P IF (filled triangles), whereas PDGF-BB could not restore a lowered P IF in ␤3 integrin null mice (open triangles). To allow comparison of the temporal changes, P IF values were normalized such that the P IF value recorded at the start of the experiment was set to 0% and P IF recorded 30 minutes after injection of C48/80 was set to Ϫ100%. For absolute P IF values and statistical analysis, see the Table. ( Figure 3B ). The latter effect of PDGF-BB, ie, to partly override the blockade by anti-␤1 integrin IgG was not observed in ␣V-negative MEF ( Figure 3B ). These findings demonstrate that PDGF-BB stimulates contractile process in vitro by a process that depends on ␣V integrins.
Discussion
Normal interstitial fluid balance is a function of fluid flux across the capillaries and the outflux via the lymphatic system. The balance between these fluxes is such that the interstitium is normally "dry" and this will also keep P IF below ambient pressure. When the fluid flux across the capillaries into the interstitium exceeds lymph flow, interstitial volume will increase and visible edema will eventually occur. Increased transcapillary flux is caused by increased capillary permeability and/or changes in the pressures acting across the capillary wall enhancing filtration. 1 The hydrostatic and colloid osmotic pressures that determine the pressure imbalance across the capillary creates the capillary filtration and also the ability to "autoregulate" the filtration across the capillary. When edema occurs, P IF will reach positive values. In contrast, we have demonstrated that inflammatory edemas are commonly associated with a lowering of P IF , 2 which then becomes an active force in generating, rather than opposing, edema formation. However, it should be noted that the lowering of P IF can only function during the initial stages of the edema formation. As the edema is being established, the increasing interstitial fluid volume will eventually raise P IF to positive values. Furthermore, once the edema has been established, and P IF is positive, the increased capillary filtration must be caused by increased capillary filtration pressure and/or capillary permeability.
The present study was performed to further elucidate the events in the connective tissue cells associated with the lowering of P IF . In particular, we have investigated the phenomenon that the lowering of P IF can be reversed, ie, the capillary net filtration pressure normalized by PDGF-BB. 7, 8 The present study demonstrates that ␤3 integrins are necessary for this effect of PDGF-BB. The ␤3 integrin subunit associates with the ␣IIb and ␣V integrin subunits to form 2 RGD-directed integrins. 29 Because the expression of ␣IIb␤3 is restricted to megakaryocytes and platelets, it may be inferred that the ␤3 integrin-dependent effect on P IF is mediated by the integrin ␣V␤3. Although a subdermal injection of PDGF-BB into naive dermis does not change P IF , PDGF-BB is able to normalize P IF that has been lowered after mast cell degranulation or blockade of ␤1 integrins. 7, 8 Similarly, P IF is not affected by perturbation of ␣V␤3 integrin function in naive dermis and P IF is normal in undisturbed dermis of ␤3-null mice (present findings). In order for PDGF-BB to normalize P IF after anaphylaxis, ␤3 must be unperturbed (present findings). Our data thus provide evidence that PDGF-BBdirected usage of ␣V␤3 for control of P IF occurs only after induction of anaphylaxis or perturbation of ␤1 integrin function. A role for ␣V␤3 in concert with PDGF in counteracting edema formation during inflammation is consistent with the reported upregulation of activated PDGF␤ receptors 30 -33 and ␣V␤3 34 in various inflammatory conditions. Based on the present findings, it is proposed that these receptors at least partly protect the inflamed tissue from the adverse effects of the inflammatory response on tissue integrity.
The tissue concentration of PDGF-BB is not known and we could not detect PDGF-BB in plasma or dermal extracts neither from normal mice nor during the acute phase of anaphylaxis (data not shown). The detection limit for the assay used was 7.7 pg/mL. In a previous immunohistochemical study, we reported that, in normal human skin, PDGF-AB/BB is confined to peripheral nerve fibers and to solitary cells of the epidermis and of the superficial dermis. 31 PDGF-BB is believed to act in a paracrine fashion where the producer cell delivers the growth factor in intercellular contacts. 35 The local concentration in these contacts is likely to be high. In the present experimental system, we injected 0.2 ng of PDGF-BB that diffused to the site where P IF was measured. Although the PDGF-BB became diluted during the diffusion, the cells at this site were exposed to a PDGF-BB concentration higher than what is likely to be present overall in normal dermis. In spite of this, we consider our experimental system physiologically relevant because the endogenous PDGF-BB is likely to have its effects locally and then in relatively high concentrations, as discussed above. It can be anticipated that during an acute systemic anaphylaxis that is a lethal condition the ␣V␤3-directed control of P IF stimulated by endogenous PDGF BB is insufficient to counteract edema formation. Rather, the presently described edemacounteracting system involving PDGF-BB and ␣V␤3 is likely to be relevant during later phases of anaphylaxis and acute inflammation. In line with this is previously reported data showing that during wound healing, as well as in carcinoma and inflammatory lesions, PDGF-AB/BB is upregulated and also detected in infiltrating macrophages and vascular cells. 31, 32, 35 The injection into a tissue, with or without adding a substance or protein normally present or not, will inflict a trauma to the tissue. In the present study, as well as previous studies on the control of P IF , we have made several attempts to control for the injection trauma as such, including vascular reactions with mobilization of leukocytes, as well as to validate the effect of the specificity of the injected protein.
Although there is an effect of the injection trauma, it has never been observed that injection of saline or unspecific proteins including nonspecific IgG elicits a lowering of P IF . 2 In contrast, IgG, cytokines, and other agents that modulate collagen gel contraction in vitro also has an in vivo action on P IF . [3] [4] [5] 7, 8 Because we have demonstrated parallel effects of a number of substances in in vivo experiments and in fibroblast-mediated collagen gel contraction in vitro, we have used the latter system as a model for P IF control in vivo. We show here that mouse embryonic fibroblasts lacking ␣V integrins, exclusively depended on ␤1 integrins to contract collagen gels even when the cells were stimulated by PDGF-BB. Wild-type fibroblasts, in contrast, contracted collagen gels when ␤1 integrins were blocked, and this contraction was stimulated by PDGF-BB. These findings show that ␣V␤3 is necessary for collagen-gel contraction when ␤1 integrins are blocked and that this process is stimulated by PDGF-BB. Several reports have shown that under certain conditions the ␣V␤3 integrin is able to mediate collagen gel contraction in vitro. 16 -19 Many inflammatory agents, including PGE 1 5 and IL-1␤, 6 induce a reduction in P IF in normal dermis and inhibit cell-mediated collagen gel contraction. The inhibitory effects on collagen gel contraction by both these agents can at least partly be overcome by stimulation with PDGF-BB. 5, 15 Further studies will be needed to investigate the hypothesis that these proinflammatory agents block ␤1 integrins but allow PDGF-BB stimulated ␣V␤3-mediated collagen-gel contraction in vitro and control of P IF in vivo.
The ligand for ␣V␤3 that is involved in P IF control in vivo is not defined and candidates include the collagen type I fibers and microfibrils. 36 Available data suggest that native triple helical interstitial collagens are not recognized by the RGD-directed integrin ␣V␤3. 37 The nature of the PDGF-BB-stimulated cell-collagen interaction mediated by ␣V␤3 that is needed for collagen gel contraction in vitro and potentially in vivo is therefore not apparent. Further studies are needed to characterize the in vivo ECM ligand that is recognized by ␣V␤3 and functions to restrain dermal tissue swelling. Regardless of the ECM ligand that is recognized by ␣V␤3 in connective tissues and/or in collagen gels in vitro, the fact that stimulation with PDGF-BB was needed for ␣V␤3-mediated contraction in vitro and in vivo suggests a requirement for activation of the integrin through inside-out signaling. 29 Such activation involves affinity modulation by conformational changes of the integrin. 38, 39 PDGF-BB-regulated activation of ␣V␤3 may thus be a suitable target for the development of pharmaceutical agents for the treatment of uncontrolled edema, eg, in septic shock.
In conclusion, the results from this study support the hypothesis that PDGF-BB counteracts a tendency to form edema by stimulating the activity of ␣V␤3-integrins. Furthermore, our data suggest that under normal conditions, tension between connective tissue cells and the dermal fibers is maintained by ␤1-integrin-mediated contraction. Proinflammatory mediators are likely to block the ␤1 integrins, causing a reduction in P IF and edema formation, a process that is opposed by PDGF-BB-directed ␣V␤3-mediated contraction.
